Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04850846 · ClinicalTrials.gov registry record · Phase 2

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

A Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
60
Enrollment target
7
Study locations

NCT04850846 is a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04850846, a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: * Metformin, extended release * Placebo ( a pill that has no active ingredients)

Conditions Studied

Smoldering Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance

Interventions

  • OTHER Placebo
  • DRUG Metformin XR

Study Locations (7)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston
  • Dana-Farber at Brighton - Brighton
  • Dana-Farber at Merrimack Valley - Methuen
  • Dana-Farber at Milford - Milford
  • DF/ BWCC in Clinical Affiliation with South Shore Hospital - Weymouth

New Hampshire

  • Dana-Farber at NHOH - Londonderry

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-04-27
Est. Completion 2027-07-31
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04850846

The ClinicalTrials.gov registry entry for NCT04850846 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04850846 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT04850846 about?

NCT04850846 is a clinical study titled "Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma". The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved i...

What is the current status of trial NCT04850846?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-04-27. Estimated completion is 2027-07-31.

What conditions does trial NCT04850846 study?

This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.

What interventions are being tested in trial NCT04850846?

The interventions under investigation include: Placebo (OTHER), Metformin XR (DRUG).

Who is sponsoring clinical trial NCT04850846?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04850846 being conducted?

This trial has 7 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoldering Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Smoldering Multiple Myeloma

All registered trials for this condition

Monoclonal Gammopathy of Undetermined Significance

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.